Hermetica Superfood Encyclopedia
The Short Answer
Campsiandra comosa bark contains β-sitosterol, lupeol, and apigenin—bioactives that exhibit free-radical scavenging via flavonoid-mediated DPPH inhibition and antiangiogenic activity across multiple tissue extract types in ex vivo assays. Preliminary in vitro screening demonstrated up to 69% antibacterial inhibition against Pseudomonas fluorescens at 1000 μg/mL and an Artemia salina LC₅₀ exceeding 1000 μg/mL, indicating low acute cytotoxicity in preclinical models.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordCampsiandra comosa benefits
Campsiandra comosa — botanical close-up
Health Benefits
**Antioxidant Activity**
Methanolic bark extracts exhibited measurable free-radical scavenging in DPPH and Fe³⁺/phenanthroline reduction assays, attributed primarily to the flavonoid apigenin (4',5,7-trihydroxyflavone), which donates hydrogen atoms to neutralize reactive oxygen species.
**Antiangiogenic Potential**
Most solvent fractions of leaves, bark, and branches demonstrated inhibition of new blood vessel formation in chick chorioallantoic membrane (CAM) assays, suggesting potential relevance to anti-tumor or anti-inflammatory contexts, though no molecular target has been identified.
**Antibacterial Properties**
Crude extracts produced bacterial inhibition halos in disk-diffusion assays, with methanolic fractions achieving up to 69% growth inhibition against Pseudomonas fluorescens at the highest tested concentration of 1000 μg/mL, indicating moderate broad-spectrum antibacterial activity.
**Low Acute Cytotoxicity**
Artemia salina brine shrimp lethality testing across all solvent extracts (hexane and methanol fractions from leaves, bark, and branches) yielded LC₅₀ values consistently above 1000 μg/mL, the conventional threshold for classifying plant extracts as non-acutely toxic in this model.
**Triterpene-Associated Bioactivity**
The isolated triterpene lupeol is a well-characterized anti-inflammatory and potential anti-neoplastic compound in the broader phytochemical literature; its presence in Campsiandra comosa bark suggests mechanistic pathways worthy of further investigation, though direct activity from this species is untested.
**Traditional Ethnomedicinal Use (Acapana)**
Regionally referenced under the traditional category 'Acapana' alongside anti-malarial plant groupings, implying historical community use for febrile and infectious conditions in Amazonian folk medicine, though formal ethnopharmacological documentation is sparse.
**Phytosterol Content**
The identification of β-sitosterol in bark fractions aligns with established phytosterol bioactivity including cholesterol biosynthesis modulation and mild immunomodulatory effects documented in other Fabaceae species, though species-specific efficacy data for Campsiandra comosa is absent.
Origin & History
Natural habitat
Campsiandra comosa is a leguminous tree endemic to Amazonian wetland ecosystems, with documented collection from Lake Catalão in the Brazilian Amazon, a seasonally flooded várzea environment. It belongs to the family Fabaceae (subfamily Caesalpinioideae) and grows in tropical floodplain forests characterized by high humidity, nutrient-rich sediment deposits, and periodic inundation. The species is part of a broader Amazonian botanical tradition where bark, leaves, and branches of riparian trees are harvested for medicinal preparations, though commercial cultivation has not been established.
“Campsiandra comosa is recognized within the broad ethnobotanical category of 'Acapana' plants used by Amazonian communities, a traditional classification that groups plants associated with treatment of malaria and febrile infectious diseases in floodplain regions of the Brazilian Amazon. The Fabaceae family to which it belongs contains numerous Amazonian species with deep-rooted medicinal traditions, including species used as astringents, anti-infectives, and febrifuges, situating Campsiandra comosa within a culturally significant botanical lineage even where specific preparation records are absent. Bark-based preparations are the most commonly implicated form in riverside Amazonian communities, where collection from flooded forest margins such as Lake Catalão represents traditional subsistence botanical practice. Formal ethnobotanical surveys have not yet systematically documented healer knowledge, preparation techniques, or indications specific to Campsiandra comosa, representing a significant gap between traditional knowledge systems and scientific literature.”Traditional Medicine
Scientific Research
The available scientific evidence for Campsiandra comosa is limited to a single primary phytochemical and bioactivity study, estimated to have been published around 2019, using in vitro and ex vivo assay systems without animal or human trial data. Methodologies employed include DPPH radical scavenging, Fe³⁺/phenanthroline antioxidant assay, Artemia salina acute toxicity screening, chick chorioallantoic membrane antiangiogenic assay, and disk-diffusion antibacterial testing—all considered preliminary screening tools rather than definitive efficacy measures. Compound isolation was confirmed for apigenin (8 mg isolated yield), lupeol, and β-sitosterol from methanolic bark fractions via column chromatography, but quantitative concentration data in the native plant material was not reported. No replicated studies, independent research groups, systematic reviews, or peer-reviewed clinical investigations exist for this species, placing the entire evidence base at the lowest tier of preclinical documentation.
Preparation & Dosage
Traditional preparation
**Traditional Decoction (Bark)**
Ethnobotanical practice in Amazonian communities suggests bark decoctions under the 'Acapana' classification, though no standardized preparation ratio, volume, or frequency has been formally documented for Campsiandra comosa specifically.
**Methanolic Extract (Research Grade)**
Laboratory studies employed crude methanolic bark, leaf, and branch extracts at concentrations of 62.5–1000 μg/mL for in vitro bioactivity screening; these concentrations are research tools and are not translatable to human supplementation doses.
**Hexane Fraction**
Hexane-partitioned fractions were tested alongside methanolic extracts in antibacterial and antiangiogenic assays; hexane branch and bark fractions were notably inactive in the CAM antiangiogenic assay, suggesting solvent-dependent bioactivity variation.
**Chromatographic Isolates**
8 mg isolated), lupeol, and β-sitosterol were purified via silica gel column chromatography using CHCl₃/MeOH gradient elution from bark methanolic fractions; no commercial standardized extract exists
Apigenin (.
**Commercial Supplement Forms**
No capsules, tablets, tinctures, or standardized commercial extracts of Campsiandra comosa are currently available or validated; any available products lack clinical dosage support.
**Recommended Human Dose**
Cannot be established from existing data; no effective dose range, bioavailability estimate, or dosing interval has been determined in any human or animal model.
Nutritional Profile
Campsiandra comosa has not been characterized for macronutrient or micronutrient composition, and no food-use application has been documented that would make a conventional nutritional profile applicable. Phytochemically, the bark yields at minimum three identified bioactive compounds: apigenin (a C-ring flavone with hydroxyl groups at positions 4', 5, and 7, contributing phenolic antioxidant capacity), lupeol (a lupane-series pentacyclic triterpene present as a minor fraction), and β-sitosterol (a Δ5-phytosterol structurally analogous to cholesterol). Quantitative concentrations of these compounds in the native plant material have not been determined; only isolation yields from laboratory-scale extractions were reported (e.g., 8 mg apigenin from an unspecified dry mass of bark). Phenolic compound content is implied by the positive antioxidant assay results but has not been quantified via total phenolic content (Folin-Ciocalteu) or HPLC profiling in published literature. Bioavailability of these compounds from any prepared form of the plant is entirely unstudied.
How It Works
Mechanism of Action
Apigenin, the primary isolated flavonoid from Campsiandra comosa bark, is known in the broader literature to scavenge free radicals through direct hydrogen atom transfer and single-electron transfer mechanisms, with affinity for DPPH and Fe³⁺ reduction systems observed empirically in bark methanolic extracts of this species. Lupeol, a pentacyclic triterpene co-isolated from bark fractions, has demonstrated NF-κB pathway inhibition and COX-2 suppression in other botanical contexts, suggesting a plausible anti-inflammatory mechanism, though this has not been verified specifically for Campsiandra comosa. β-Sitosterol, the third identified compound, is structurally analogous to cholesterol and competitively inhibits intestinal cholesterol absorption via Niemann-Pick C1-Like 1 (NPC1L1) transporter interference in established models, with immunomodulatory effects potentially mediated through altered prostaglandin signaling. The antiangiogenic activity observed in CAM assays across most extract fractions lacks mechanistic characterization for this species, but may reflect interference with VEGF signaling or matrix metalloproteinase activity, pathways modulated by apigenin and lupeol in other studied systems.
Clinical Evidence
No clinical trials, observational cohort studies, or controlled animal experiments have been conducted on Campsiandra comosa. The totality of evidence derives from in vitro cell-free assays and one ex vivo chick embryo model, none of which provide clinically translatable effect sizes, therapeutic indices, or pharmacokinetic data. Antibacterial inhibition of 69% against Pseudomonas fluorescens at 1000 μg/mL is a concentration far exceeding any achievable plasma level from oral administration with current extract forms, limiting direct clinical interpretation. Confidence in any therapeutic claim is very low; the data serve only as a rationale for future phytochemical isolation and preclinical pharmacology studies.
Safety & Interactions
Campsiandra comosa exhibits low acute cytotoxicity in the Artemia salina brine shrimp model, with LC₅₀ values exceeding 1000 μg/mL across all tested solvent fractions—the conventional threshold below which plant extracts are classified as non-acutely toxic in this surrogate screen—but this model has limited predictive validity for chronic human toxicity or organ-specific adverse effects. No subacute, subchronic, or chronic toxicity studies, genotoxicity assays, or human adverse event reports exist for this species, meaning the absence of documented harm reflects a lack of data rather than established safety. Drug interaction potential is unknown; however, the presence of apigenin, a compound with documented CYP450 enzyme inhibitory activity (particularly CYP1A2 and CYP2C9) in isolated form, raises theoretical concern for pharmacokinetic interactions with co-administered medications metabolized by these enzymes, though this has not been tested for Campsiandra comosa extracts. Use during pregnancy, lactation, or in pediatric populations is contraindicated by default given the complete absence of safety data; no maximum safe dose has been established for any human population.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Campsiandra comosa Benth.Acapana (traditional classification)Amazonian legume barkFabaceae Campsiandra
Frequently Asked Questions
What is Campsiandra comosa used for traditionally?
Campsiandra comosa is traditionally grouped under the Amazonian medicinal category 'Acapana,' which encompasses plants used by riverside communities in the Brazilian Amazon for conditions including malaria and febrile infections. However, formal ethnobotanical records specifically detailing its preparation methods, dosing, or treated ailments for this species have not been systematically published. Scientific research confirming these traditional uses in clinical or animal models does not yet exist.
What active compounds are found in Campsiandra comosa?
Phytochemical isolation from methanolic bark extracts has identified three main bioactive compounds: apigenin (a flavone antioxidant, 4',5,7-trihydroxyflavone), lupeol (a pentacyclic lupane-series triterpene), and β-sitosterol (a phytosterol). Apigenin was isolated in a yield of 8 mg from laboratory-scale fractionation using CHCl₃/MeOH gradient chromatography. Quantitative concentrations of these compounds in the native plant tissue have not been reported.
Is Campsiandra comosa safe to consume?
Artemia salina brine shrimp toxicity screening showed LC₅₀ values greater than 1000 μg/mL for all tested fractions, indicating low acute cytotoxicity in this preliminary model. However, no chronic toxicity studies, human safety data, or clinical adverse event reports exist for Campsiandra comosa, so its long-term safety profile in humans is entirely unknown. Its use during pregnancy or lactation is not recommended given the absence of any safety characterization.
Are there any clinical trials on Campsiandra comosa?
No clinical trials—human or animal—have been conducted on Campsiandra comosa. All available research is limited to in vitro bioactivity assays (DPPH antioxidant, antibacterial disk-diffusion) and one ex vivo chick chorioallantoic membrane antiangiogenic assay, based on a single primary study. The evidence base is entirely preclinical, and no therapeutic conclusions can be drawn for human application.
What dose of Campsiandra comosa extract is effective?
No human-relevant effective dose has been established for Campsiandra comosa. In vitro studies used crude extract concentrations ranging from 62.5 to 1000 μg/mL, with the maximum antibacterial inhibition (69% against Pseudomonas fluorescens) observed at 1000 μg/mL. These laboratory concentrations are not pharmacokinetically translatable to oral supplementation doses, and no bioavailability data, pharmacokinetic studies, or clinical dose-finding trials have been performed.
How does the extraction method affect the antioxidant potency of Campsiandra comosa?
Methanolic extraction of Campsiandra comosa bark has demonstrated superior antioxidant activity compared to other solvents, as evidenced by DPPH and Fe³⁺/phenanthroline reduction assays. The methanol-based extraction process appears to optimize the preservation and bioavailability of key flavonoid compounds, particularly apigenin, which is responsible for the free-radical scavenging effects. Different extraction methods may yield varying concentrations of active constituents, making solvent selection a critical factor in supplement efficacy.
What is the relationship between apigenin content and Campsiandra comosa's antioxidant effects?
Apigenin (4',5,7-trihydroxyflavone) is the primary bioactive flavonoid in Campsiandra comosa responsible for its measurable antioxidant activity through a hydrogen-donation mechanism that neutralizes reactive oxygen species. This compound directly contributes to the ingredient's free-radical scavenging capacity demonstrated in laboratory assays. The concentration of apigenin in extracts directly correlates with the antioxidant potency observed in standardized testing.
Does Campsiandra comosa have potential benefits beyond antioxidant activity?
Beyond antioxidant effects, solvent fractions derived from Campsiandra comosa leaves, bark, and branches have demonstrated antiangiogenic potential, suggesting inhibitory activity against blood vessel formation. This indicates the plant may have a broader spectrum of bioactive properties beyond oxidative stress reduction. However, further research is needed to characterize the clinical significance and mechanisms of these additional effects.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w campsiandra-comosa-campsiandra-comosa-benth curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
